Exact Sciences
In Brief This Week: Count Me In, TeleRare Health, VolitionRx, Ascentage, Atsena, ClearNote Health
News items for the week of March 10, 2025.
Flatiron Health, Exact Sciences Partner on Study of Molecular Residual Disease Test
The collaborators have enrolled their first patient in a prospective clinical study testing a tumor-informed assay for monitoring recurrence across multiple cancers.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.
In an indirect comparison study by researchers in Germany, a fecal immunochemical test showed similar sensitivity and specificity as Exact Sciences' Cologuard Plus test.